These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 33275608)

  • 41. Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12ΔNSm21/384 vaccine candidate for sheep, goats and calves.
    Boumart Z; Daouam S; Bamouh Z; Jazouli M; Tadlaoui KO; Dungu B; Bettinger G; Watts DM; Elharrak M
    Vaccine; 2019 Mar; 37(12):1642-1650. PubMed ID: 30773401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of a recombinant Rift Valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep.
    Weingartl HM; Nfon CK; Zhang S; Marszal P; Wilson WC; Morrill JC; Bettinger GE; Peters CJ
    Vaccine; 2014 Apr; 32(20):2345-9. PubMed ID: 24462482
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus.
    Nunes SF; Hamers C; Ratinier M; Shaw A; Brunet S; Hudelet P; Palmarini M
    J Virol; 2014 Nov; 88(21):12222-32. PubMed ID: 25142610
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetically Modified Rabies Virus Vector-Based Rift Valley Fever Virus Vaccine is Safe and Induces Efficacious Immune Responses in Mice.
    Zhang S; Hao M; Feng N; Jin H; Yan F; Chi H; Wang H; Han Q; Wang J; Wong G; Liu B; Wu J; Bi Y; Wang T; Sun W; Gao Y; Yang S; Zhao Y; Xia X
    Viruses; 2019 Oct; 11(10):. PubMed ID: 31597372
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Comtet L; Lövgren Bengtsson K; Pringle J; Zientara S; Valarcher JF
    Clin Vaccine Immunol; 2013 Aug; 20(8):1115-22. PubMed ID: 23720365
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of a Double-Antigen Microsphere Immunoassay for Simultaneous Group and Serotype Detection of Bluetongue Virus Antibodies.
    Breard E; Garnier A; Despres P; Blaise Boisseau S; Comtet L; Viarouge C; Bakkali-Kassimi L; Pourquier P; Hudelet P; Vitour D; Rossi S; Belbis G; Sailleau C; Zientara S
    Transbound Emerg Dis; 2017 Dec; 64(6):1837-1847. PubMed ID: 27667484
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancy.
    Wichgers Schreur PJ; van Keulen L; Kant J; Kortekaas J
    Vaccine; 2017 May; 35(23):3123-3128. PubMed ID: 28457675
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Generation of Recombinant Modified Vaccinia Virus Ankara Encoding VP2, NS1, and VP7 Proteins of Bluetongue Virus.
    Marín-López A; Ortego J
    Methods Mol Biol; 2016; 1349():137-50. PubMed ID: 26458834
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DNA vaccine prime and recombinant FPV vaccine boost: an important candidate immunization strategy to control bluetongue virus type 1.
    Li J; Yang T; Xu Q; Sun E; Feng Y; Lv S; Zhang Q; Wang H; Wu D
    Appl Microbiol Biotechnol; 2015 Oct; 99(20):8643-52. PubMed ID: 26048472
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protective duration of immunity of an inactivated bluetongue (BTV) serotype 2 vaccine against a virulent BTV serotype 2 challenge in sheep.
    Hamers C; Rehbein S; Hudelet P; Blanchet M; Lapostolle B; Cariou C; Duboeuf M; Goutebroze S
    Vaccine; 2009 May; 27(21):2789-93. PubMed ID: 19366576
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccines against bluetongue in Europe.
    Savini G; MacLachlan NJ; Sanchez-Vizcaino JM; Zientara S
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):101-20. PubMed ID: 17765305
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A single-cycle replicable Rift Valley fever phlebovirus vaccine carrying a mutated NSs confers full protection from lethal challenge in mice.
    Terasaki K; Juelich TL; Smith JK; Kalveram B; Perez DD; Freiberg AN; Makino S
    Sci Rep; 2018 Nov; 8(1):17097. PubMed ID: 30459418
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Presence of Antibodies against Bluetongue Virus (BTV) in Sheep 5 to 7.5 Years after Vaccination with Inactivated BTV-8 Vaccines.
    Hilke J; Strobel H; Woelke S; Stoeter M; Voigt K; Moeller B; Bastian M; Ganter M
    Viruses; 2019 Jun; 11(6):. PubMed ID: 31181733
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge.
    Wade-Evans AM; Romero CH; Mellor P; Takamatsu H; Anderson J; Thevasagayam J; Fleming MJ; Mertens PP; Black DN
    Virology; 1996 Jun; 220(1):227-31. PubMed ID: 8659119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune correlates of protection of the four-segmented Rift Valley fever virus candidate vaccine in mice.
    Prajeeth CK; Zdora I; Saletti G; Friese J; Gerlach T; Wilken L; Beicht J; Kubinski M; Puff C; Baumgärtner W; Kortekaas J; Wichgers Schreur PJ; Osterhaus ADME; Rimmelzwaan GF
    Emerg Microbes Infect; 2024 Dec; 13(1):2373313. PubMed ID: 38946528
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the humoral response between sheep vaccinated with a killed-virus vaccine and those vaccinated with a modified-live virus vaccine against bluetongue virus serotype 17.
    Speiser KL; Schumaker BA; Cook WE; Cornish TE; Cammack KM; Miller MM
    J Am Vet Med Assoc; 2016 May; 248(9):1043-9. PubMed ID: 27074613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of cross-protection of bluetongue virus serotype 4 with other serotypes in sheep.
    Zulu GB; Venter EH
    J S Afr Vet Assoc; 2014 Oct; 85(1):1041. PubMed ID: 25686101
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serological Cross-Reactions between Expressed VP2 Proteins from Different Bluetongue Virus Serotypes.
    Fay PC; Mohd Jaafar F; Batten C; Attoui H; Saunders K; Lomonossoff GP; Reid E; Horton D; Maan S; Haig D; Daly JM; Mertens PPC
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452321
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep.
    Faburay B; Lebedev M; McVey DS; Wilson W; Morozov I; Young A; Richt JA
    Vector Borne Zoonotic Dis; 2014 Oct; 14(10):746-56. PubMed ID: 25325319
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of protection afforded by a bivalent virus-like particle vaccine against bluetongue virus serotypes 1 and 4 in sheep.
    Pérez de Diego AC; Athmaram TN; Stewart M; Rodríguez-Sánchez B; Sánchez-Vizcaíno JM; Noad R; Roy P
    PLoS One; 2011; 6(10):e26666. PubMed ID: 22046324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.